Companion Medical wins FDA nod for InPen insulin pen
Companion Medical said today it won FDA 510(k) approval for its wireless-enabled InPen insulin pen and mobile application. The InPen is designed to connect to smartphones via bluetooth and send data back, including insulin dosage and timing, the company said. The app allows patients to track and calculate doses, and set alarms for future doses. “FDA clearance of the InPen and mobile app represents a significant advancement in diabetes care. The product combines the benefits of sophisticated insulin pumps with the simplicity and affordability of pens and syringes, providing patients, physicians, and caregivers increas...
Source: Mass Device - July 27, 2016 Category: Medical Equipment Authors: Fink Densford Tags: 510(k) Diabetes Food & Drug Administration (FDA) Regulatory/Compliance Companion Medical Source Type: news

Mannkind taps medtech reps after Sanofi deal fails
Mannkind chief commercial officer Michael Castagna is trying to resuscitate the inhaled insulin maker after its co-marketing agreement with Sanofi (NYSE:SNY) was cancelled at the beginning of the year due to disappointing sales. He’s fielding a team of about 70 people to sell the company’s Afrezza insulin inhaler, with about ⅓ coming from the medical device industry. “We are looking to build a high energy nimble company that reflects the speed of the medical device industry, articulation of the science from biotech and a relentless focus on helping patients suffering from diabetes,” Castagna told Fortune. But at ...
Source: Mass Device - June 28, 2016 Category: Medical Equipment Authors: Varun Saxena Tags: Business/Financial News Diabetes Drug-Device Combinations Mannkind Corp. Sanofi-Aventis newtag Source Type: news

Humalog (Insulin Lispro (Human Analog)) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - May 17, 2016 Category: Drugs & Pharmacology Source Type: news

Insulet deals Neighborhood Diabetes biz to Liberty Med for $5m
Insulet (NSDQ:PODD) said today it’s selling its Neighborhood Diabetes supplies biz to mail order medical supply company Liberty Medical for $5 million in cash, $58 million less than the company paid for it in 2011. The Billerica, Mass.-based company said it expects the sale to close sometime in the 1st quarter, and said it expects the sale to improve the company’s gross margins annually by low-to-mid single digits. When Insulet picked up Neighborhood Diabetes for $63 million in June 2011, the purchase tripled Insulet’s customer base, according to the company. Insulet CFO Brian Roberts told MassDevice.com at...
Source: Mass Device - February 2, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Business/Financial News Diabetes Mergers & Acquisitions Insulet Corp. Source Type: news

MassDevice.com +3 | The top 3 medtech stories for January 12, 2016
Say hello to MassDevice +3, a bite-sized view of the top three medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.   3. Insulet inks deal for Lilly’s Humalog concentrated insulin Insulet said yesterday that it inked a deal with Eli Lilly to develop a version of its flagship OmniPod device that uses a concentrated insulin made by the pharma giant. Lilly’s Humalog U200, which delivers 200 units of insulin per...
Source: Mass Device - January 12, 2016 Category: Medical Equipment Authors: MassDevice Tags: News Well Plus 3 Source Type: news

Insulet inks deal for Lilly’s Humalog concentrated insulin
Insulet (NSDQ:PODD) said yesterday that it inked a deal with Eli Lilly (NYSE:LLY) to develop a version of its flagship OmniPod device that uses a concentrated insulin made by the pharma giant. Lilly’s Humalog U200, which delivers 200 units of insulin per milliliter, is for patients who need higher doses of insuling to control their diabetes, Billerica, Mass.-based Insulet said. The deal calls for the companies to evaluate the use of Humalog U200 in the OmniPod insulin delivery system. “We are thrilled to partner with Lilly to develop the first insulin pump specifically designed for Humalog U200 insulin,̶...
Source: Mass Device - January 12, 2016 Category: Medical Equipment Authors: Brad Perriello Tags: Diabetes Pharmaceuticals Eli Lilly & Co. Insulet Corp. Source Type: news

Adocia and Lilly begin Phase Ib trial of BioChaperone Lispro to treat type 2 diabetes
Adocia and Eli Lilly have started a Phase Ib clinical trial evaluating BioChaperone Lispro, an ultra-rapid formulation of insulin lispro licensed to Lilly for the treatment of patients with type 2 diabetes. (Source: Drug Development Technology)
Source: Drug Development Technology - September 30, 2015 Category: Pharmaceuticals Source Type: news

Bigfoot acquires Asante assets, inks deal with Dexcom
Bigfoot Biomedical is making strides towards its goal of a bionic pancreas after inking a deal with Dexcom Inc. (NSDQ:DXCM), maker of continuous glucose monitors, and acquiring the assets of shuttered insulin pump maker Asante. Bigfoot also said it will be relocating to Milpitas, Calif., where Asante was headquartered. The deal signed with Dexcom is slated to allow Bigfoot to integrate data from Dexcom’s continuous glucose monitoring systems into its insulin delivery system, it said last week. The deal makes sense, as the “homebrew artificial pancreas” system created by Bigfoot co-founder Bryan Mazlish...
Source: Mass Device - June 9, 2015 Category: Medical Equipment Authors: Fink Densford Tags: Business/Financial News Diabetes Mergers & Acquisitions mHealth (Mobile Health) Asante Solutions Bigfoot Biomedical DexCom Inc. newtag Source Type: news

Biodel Reports Positive Top-Line Results From Clinical Study Of Ultra-Rapid-Acting Insulin Analog Candidates
Biodel Inc. (Nasdaq:BIOD) today announced positive top-line results from a Phase 1 clinical trial of two ultra-rapid-acting insulin analog-based formulations, BIOD-238 and BIOD-250, conducted to evaluate the pharmacokinetic and injection site toleration profiles relative to Humalog®, a rapid-acting insulin analog. (Source: Pharmaceutical Online News)
Source: Pharmaceutical Online News - January 25, 2013 Category: Pharmaceuticals Source Type: news